Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H31N3O5 |
| Molecular Weight | 453.5307 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(OC[C@@H](O)CO)C(C)=CC(=C1)C2=NOC(=N2)C3=CC(=NC(OC)=C3)C4CCCC4
InChI
InChIKey=KJKKMMMRWISKRF-FQEVSTJZSA-N
InChI=1S/C25H31N3O5/c1-4-16-10-18(9-15(2)23(16)32-14-20(30)13-29)24-27-25(33-28-24)19-11-21(17-7-5-6-8-17)26-22(12-19)31-3/h9-12,17,20,29-30H,4-8,13-14H2,1-3H3/t20-/m0/s1
| Molecular Formula | C25H31N3O5 |
| Molecular Weight | 453.5307 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cenerimod is an orally available sphingosine-1-phosphate receptor 1 (S1P1) modulator that is being developed by Idorsia Pharmaceuticals for the treatment of systemic lupus erythematosus. Sphingosine-1-phosphate (S1P), a lipid mediator, regulates lymphocyte migration between lymphoid tissue and blood. Cenerimod is a potent, selective, safe and orally administrable S1P1 receptor modulator, which reportedly reduced blood lymphocytes and attenuated murine experimental autoimmune encephalomyelitis (EAE) in a murine model. Cenerimod has potential as novel therapy with an improved safety profile for autoimmune diseases with a high unmet medical need.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:39:18 GMT 2025
by
admin
on
Mon Mar 31 23:39:18 GMT 2025
|
| Record UNII |
Y333RS1786
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10183
Created by
admin on Mon Mar 31 23:39:18 GMT 2025 , Edited by admin on Mon Mar 31 23:39:18 GMT 2025
|
PRIMARY | |||
|
300000010606
Created by
admin on Mon Mar 31 23:39:18 GMT 2025 , Edited by admin on Mon Mar 31 23:39:18 GMT 2025
|
PRIMARY | |||
|
C169837
Created by
admin on Mon Mar 31 23:39:18 GMT 2025 , Edited by admin on Mon Mar 31 23:39:18 GMT 2025
|
PRIMARY | |||
|
1262414-04-9
Created by
admin on Mon Mar 31 23:39:18 GMT 2025 , Edited by admin on Mon Mar 31 23:39:18 GMT 2025
|
PRIMARY | |||
|
49871973
Created by
admin on Mon Mar 31 23:39:18 GMT 2025 , Edited by admin on Mon Mar 31 23:39:18 GMT 2025
|
PRIMARY | |||
|
Y333RS1786
Created by
admin on Mon Mar 31 23:39:18 GMT 2025 , Edited by admin on Mon Mar 31 23:39:18 GMT 2025
|
PRIMARY | |||
|
DB12705
Created by
admin on Mon Mar 31 23:39:18 GMT 2025 , Edited by admin on Mon Mar 31 23:39:18 GMT 2025
|
PRIMARY | |||
|
EF-116
Created by
admin on Mon Mar 31 23:39:18 GMT 2025 , Edited by admin on Mon Mar 31 23:39:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Emax = 126%. Chinese Hamster Ovary (CHO) cells, overexpressing human S1P1 receptor (35S)-GTP-S incorporation assays.
EC50
|
||
|
OFF TARGET->WEAK AGONIST |
Chinese Hamster Ovary (CHO) cells, overexpressing human S1P4 receptor (35S)-GTP-S incorporation assays.
EC50
|
||
|
OFF TARGET->NON-INHIBITOR |
Chinese Hamster Ovary (CHO) cells, overexpressing human S1P2 receptor (35S)-GTP-S incorporation assays.
EC50
|
||
|
OFF-TARGET->AGONIST |
Chinese Hamster Ovary (CHO) cells, overexpressing human S1P3 receptor (35S)-GTP-S incorporation assays.
EC50
|
||
|
TARGET -> AGONIST |
Chinese Hamster Ovary (CHO) cells, overexpressing human S1P5 receptor (35S)-GTP-S incorporation assays.
EC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
